Conclusion
Administration of rosiglitazone can improve some of the pathophysiological trademarks related with preeclampsia and may prove useful for the prevention of the development and progression of this condition. However, human trials are necessary to prove this hypothesis.
Objective
To investigate the role of peroxisome proliferator-activated receptor (PPAR)-γ agonist on renal functions and blood levels of vasoregulatory peptides by administering rosiglitazone-a PPAR-γ agonist- to nitric oxide (NO) synthase lacking pregnant rats as a creature model of preeclampsia. Study design: Experimental study. Place and duration of study: Medical College at King Khaled University Hospital, Riyadh, Saudi Arabia, from July 2016 to May 2017. Methodology: One hundred female rats were divided into four equal groups; virgin non-pregnant, pregnant salinereceived, pregnant treated with NG-nitro-L-arginine-methyl-ester (L-NAME) to produce preeclampsia and the last group received L-NAME+rosiglitazone. Some renal function tests and blood level of vasoregulatory factors were measured on day 13 and day 20 of pregnancy. Pup weight was also measured.
Results
L-NAME treated rats exhibited all classic hallmarks of preeclampsia. Rosiglitazone treatment from days 14 to 20 ameliorated hypertension, improved renal function, decreased endothelin-1 (ET-1), angiotensin II (Ag II) and interleukin (IL-6), while it increases NO level and pup weight.